Heron Therapeutics vs UroGen Pharma
HRTX and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRTX and URGN compare
UroGen Pharma is the larger company, worth 27 times as much as Heron Therapeutics ($1.5B against $53.6M).
UroGen Pharma grew revenue faster over the last twelve months (100% versus 0.99% for Heron Therapeutics).
Heron Therapeutics keeps more of each dollar of sales as profit, with a net margin of −22.5% compared with −51.7% at UroGen Pharma.
Heron Therapeutics scores higher on the StockData Score (8 against 6 for UroGen Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRTX | URGN |
|---|---|---|
| Size and price | ||
| Market cap | $53.6M | $1.5B |
| Share price | $0.282 | $29.87 |
| Change, 1 year | −74.3% | 25.7% |
| Change, 5 years | −97.0% | 146% |
| Beta (5Y) | 2.95 | 2.73 |
| Employees | 128 | 291 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 7.7× |
| P/B | 7.8× | – |
| FCF yield | −22.6% | −10.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.99% | 100% (better) |
| Revenue growth, 5Y average | 11.8% | 56.2% (better) |
| Profitability | ||
| Gross margin | 70.1% | 90.8% (better) |
| Operating margin | −7.2% (better) | −35.3% |
| Net margin | −22.5% (better) | −51.7% |
| FCF margin | −8.0% (better) | −84.3% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.49 | 3.80 (better) |
| Altman Z-score | −9.60 | −2.55 (better) |
| Piotroski F-score | 4 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 70.4% | 86.8% |
| Held by insiders | 21.6% | 5.6% |
| Insider net buying, 12 months | – | −$4.5M |
| Short interest, % of float | 22.8% | 11.1% |
Go deeper
- HRTX stock overview
- HRTX income statement
- HRTX valuation and score
- URGN stock overview
- URGN income statement
- URGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.